SCHEMBL23645328

SCHEMBL23645328

CCOC(=O)c1nc2n(c1-c1cccc(Cl)n1)CCCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
ALDH1A1 P00352 3/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
KDM4E B2RXH2 3/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 3/20 0.41
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 3/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP1A2 P05177 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 2/20 0.38
TPH1 P17752 1/20 0.37
TPH2 Q8IWU9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31069248 1.00 MAPT (0.44) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL21810872 0.86 MAPT (0.43) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL31069250 0.84 TGFBR1 (0.46) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL23645429 0.84 TGFBR1 (0.46) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL28635156 0.83 POLB (0.44) ALDH1A1RAB9AKDM4EKMT2AMEN1
SCHEMBL12683108 0.75 GRM5 (0.47) ALDH1A1RAB9ANPC1KDM4EHSD17B10
SCHEMBL23645338 0.73 MAPT (0.53) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL21357773 0.73 MAPT (0.53) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL23645315 0.71 NR4A2 (0.40) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL31069233 0.71 NR4A2 (0.40) MAPTALDH1A1RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2025-09-23 US disclosed
EP-3851436-B1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2024-06-12 EP disclosed
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2023-03-23 US disclosed
EP-3851436-A1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2021-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A MAPT 4617/4885ALDH1A1 1627/4885RAB9A 1336/4885
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A MAPT 4572/4885ALDH1A1 1596/4885RAB9A 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.